Background:Limitations in the use of antiretroviral therapy suggest the need for additional approaches to enhance immune restoration and the control of HIV-1 replication. Therefore, we evaluated the clinical tolerance and biological effects of immunotherapy with the synthetic immunomodulator Murabutide in 9 treatment-na¨lve HIV-1 patients presenting with CD4+ lymphocyte counts >500 cells/mm3 and plasma viral loads

Keywords: Acetylmuramyl-Alanyl-Isoglutamine - administration & dosage, Acetylmuramyl-Alanyl-Isoglutamine - analogs & derivatives, Acetylmuramyl-Alanyl-Isoglutamine - toxicity, Acquired Immunodeficiency Syndrome - drug therapy, Acquired Immunodeficiency Syndrome - immunology, Adjuvants, Immunologic - administration & dosage, Adjuvants, Immunologic - toxicity, Anti-HIV Agents - administration & dosage, Anti-HIV Agents - therapeutic use, Antigens, CD - blood, Antigens, CD - drug effects, CD4 Lymphocyte Count, Drug Administration Schedule, Injections, Subcutaneous, Lymphocyte Activation - drug effects